Macular Degeneration Clinical Trials in Augusta, Georgia

8 recruitingAugusta, Georgia

Showing 18 of 8 trials

Recruiting
Phase 3

Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS)

Neovascular Age-Related Macular Degeneration (nAMD)Wet AMD
Adverum Biotechnologies, Inc.284 enrolled36 locationsNCT07482176
Recruiting

A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic Atrophy

Geographic AtrophyMacular Degeneration
Astellas Pharma Global Development, Inc.1,000 enrolled65 locationsNCT06779773
Recruiting
Phase 3

Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)

Neovascular Age-related Macular Degeneration
AbbVie561 enrolled100 locationsNCT07007065
Recruiting
Phase 4

A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)

Neovascular Age-related Macular Degeneration
Genentech, Inc.188 enrolled50 locationsNCT04853251
Recruiting
Phase 3

Home OCT-Guided Treatment Versus Treat and Extend for the Management of Neovascular AMD

Neovascular Age-related Macular Degeneration
Jaeb Center for Health Research600 enrolled64 locationsNCT05904028
Recruiting
Phase 1Phase 2

A Safety and Efficacy Study of One-time SAR402663 in Adults With Neovascular Age-related Macular Degeneration

Neovascular Age-related Macular Degeneration
Sanofi66 enrolled18 locationsNCT06660667
Recruiting
Phase 3

Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration

Neovascular Age-Related Macular Degeneration (nAMD)Wet AMD
Adverum Biotechnologies, Inc.284 enrolled79 locationsNCT06856577
Recruiting
Phase 1

Study to Evaluate the Safety of CG-P5 Peptide Eye Drops in Patients Diagnosed With Age-related Wet Macular Degeneration

Age-related Wet Macular Degeneration
Caregen Co. Ltd.45 enrolled7 locationsNCT06132035